PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28835573-10 2017 Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Tegafur 54-68 dihydropyrimidine dehydrogenase Homo sapiens 162-165 21378348-14 2011 Thus, the DPD inhibitory action of CDHP contributes to a decrease in 5-FU catabolism and to significantly higher blood levels of 5-FU compared to FT alone. Tegafur 146-148 dihydropyrimidine dehydrogenase Homo sapiens 10-13 23585145-1 2013 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur). Tegafur 145-152 dihydropyrimidine dehydrogenase Homo sapiens 0-31 23585145-1 2013 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of 5-fluorouracil (5-FU) and its derivatives (capecitabine and tegafur). Tegafur 145-152 dihydropyrimidine dehydrogenase Homo sapiens 33-36 26651493-1 2016 DPD is the rate-limiting enzyme involved in the metabolism of 5-fluorouracil and its prodrugs, capecitabine and tegafur. Tegafur 112-119 dihydropyrimidine dehydrogenase Homo sapiens 0-3 17695427-0 2007 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Tegafur 160-163 dihydropyrimidine dehydrogenase Homo sapiens 45-76 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 189-197 dihydropyrimidine dehydrogenase Homo sapiens 33-36 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 199-202 dihydropyrimidine dehydrogenase Homo sapiens 0-31 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 199-202 dihydropyrimidine dehydrogenase Homo sapiens 33-36 19015148-1 2009 BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas. Tegafur 95-98 dihydropyrimidine dehydrogenase Homo sapiens 205-236 19015148-1 2009 BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas. Tegafur 95-98 dihydropyrimidine dehydrogenase Homo sapiens 238-241 20146975-1 2010 Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of fluoropyrimidines, such as 5-Fluorouracil and its oral prodrugs derivatives, including capecitabine and ftorafur (UFT, S1). Tegafur 189-197 dihydropyrimidine dehydrogenase Homo sapiens 0-31 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. Tegafur 49-56 dihydropyrimidine dehydrogenase Homo sapiens 132-163 17603216-2 2007 UFT is a combination preparation of tegafur with uracil, which also inhibits DPD, though less potently; UFT has a higher content of tegafur than that in TS-1. Tegafur 36-43 dihydropyrimidine dehydrogenase Homo sapiens 77-80 17603216-4 2007 METHODS: We developed a model incorporating the inhibition of DPD by gimeracil and uracil, and fitted the model to the observed kinetics of tegafur and 5-FU after the administration of TS-1 and UFT. Tegafur 140-147 dihydropyrimidine dehydrogenase Homo sapiens 62-65 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. Tegafur 49-56 dihydropyrimidine dehydrogenase Homo sapiens 165-168 17143493-7 2007 In contrast, DPD activity was increased by NAC with UFT administration, but its increased activity was significantly inhibited by the addition of CPA. Tegafur 52-55 dihydropyrimidine dehydrogenase Homo sapiens 13-16 17952005-0 2007 Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. Tegafur 98-105 dihydropyrimidine dehydrogenase Homo sapiens 0-31 17143493-0 2007 Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. Tegafur 64-71 dihydropyrimidine dehydrogenase Homo sapiens 86-117 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 80-87 dihydropyrimidine dehydrogenase Homo sapiens 191-222 16897985-8 2006 It has a component that enhances the cytotoxic activity of tegafur by inhibiting dihydropyrimidine dehydrogenase (DPD) and also has a component that reduces phosphorylation of 5-fluorouracil in the gastrointestinal tract to potentially reduce toxicity. Tegafur 59-66 dihydropyrimidine dehydrogenase Homo sapiens 81-112 16897985-8 2006 It has a component that enhances the cytotoxic activity of tegafur by inhibiting dihydropyrimidine dehydrogenase (DPD) and also has a component that reduces phosphorylation of 5-fluorouracil in the gastrointestinal tract to potentially reduce toxicity. Tegafur 59-66 dihydropyrimidine dehydrogenase Homo sapiens 114-117 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 80-87 dihydropyrimidine dehydrogenase Homo sapiens 224-227 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 89-91 dihydropyrimidine dehydrogenase Homo sapiens 191-222 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. Tegafur 89-91 dihydropyrimidine dehydrogenase Homo sapiens 224-227 15598584-6 2005 Furthermore, heterogeneous expression of DPD was more effective than homogeneous expression of DPD in neoplastic cells when evaluated in patients treated with chemotherapy including tegafur/uracil (UFT). Tegafur 182-196 dihydropyrimidine dehydrogenase Homo sapiens 41-44 15598584-6 2005 Furthermore, heterogeneous expression of DPD was more effective than homogeneous expression of DPD in neoplastic cells when evaluated in patients treated with chemotherapy including tegafur/uracil (UFT). Tegafur 198-201 dihydropyrimidine dehydrogenase Homo sapiens 41-44 15363468-9 2004 The goal of this article is to review the literature concerning the treatment of elderly patients with UFT, an orally administered dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. Tegafur 103-106 dihydropyrimidine dehydrogenase Homo sapiens 131-162 15363468-9 2004 The goal of this article is to review the literature concerning the treatment of elderly patients with UFT, an orally administered dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine. Tegafur 103-106 dihydropyrimidine dehydrogenase Homo sapiens 164-167 12851836-12 2003 DPD inhibitory fluoropyrimidines (DIFs), including uracil plus tegafur (UFT) and tegafur plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate, in a molar ratio of 1:0.4:1 (TS-1), have recently been used in clinical settings. Tegafur 63-70 dihydropyrimidine dehydrogenase Homo sapiens 0-3 14551502-2 2003 DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid). Tegafur 89-92 dihydropyrimidine dehydrogenase Homo sapiens 0-3 12851836-12 2003 DPD inhibitory fluoropyrimidines (DIFs), including uracil plus tegafur (UFT) and tegafur plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate, in a molar ratio of 1:0.4:1 (TS-1), have recently been used in clinical settings. Tegafur 72-75 dihydropyrimidine dehydrogenase Homo sapiens 0-3 12464897-10 2002 Although TS showed no correlation between tegafur-uracil response and TS labeling index, there was a significant correlation between the tegafur-uracil response and DPD-LI. Tegafur 137-151 dihydropyrimidine dehydrogenase Homo sapiens 165-168 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. Tegafur 165-172 dihydropyrimidine dehydrogenase Homo sapiens 53-56 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 dihydropyrimidine dehydrogenase Homo sapiens 205-236 11679189-4 2001 Orzel [UFT (uracil:tegafur) plus oral leucovorin] is the first oral DPD-inhibitory fluoropyrimidine. Tegafur 7-10 dihydropyrimidine dehydrogenase Homo sapiens 68-71 11219978-2 2001 Tegafur, a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU by the hepatic cytochrome P450 pathway, whereas uracil enhances the half-life of converted 5-FU leading to prolonged exposure and higher intracellular concentration of 5-FU by inhibiting dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism. Tegafur 0-7 dihydropyrimidine dehydrogenase Homo sapiens 253-284 11219978-2 2001 Tegafur, a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU by the hepatic cytochrome P450 pathway, whereas uracil enhances the half-life of converted 5-FU leading to prolonged exposure and higher intracellular concentration of 5-FU by inhibiting dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in 5-FU catabolism. Tegafur 0-7 dihydropyrimidine dehydrogenase Homo sapiens 286-289 10595802-4 1999 Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD"s activity. Tegafur 79-82 dihydropyrimidine dehydrogenase Homo sapiens 179-182 10595802-4 1999 Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD"s activity. Tegafur 84-91 dihydropyrimidine dehydrogenase Homo sapiens 179-182 12355409-0 2002 Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer. Tegafur 135-138 dihydropyrimidine dehydrogenase Homo sapiens 20-51 12355409-0 2002 Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer. Tegafur 140-147 dihydropyrimidine dehydrogenase Homo sapiens 20-51 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 dihydropyrimidine dehydrogenase Homo sapiens 139-170 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). Tegafur 71-78 dihydropyrimidine dehydrogenase Homo sapiens 172-175 11729480-0 2001 [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity]. Tegafur 77-80 dihydropyrimidine dehydrogenase Homo sapiens 99-102 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 92-99 dihydropyrimidine dehydrogenase Homo sapiens 238-241 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 dihydropyrimidine dehydrogenase Homo sapiens 205-236 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. Tegafur 101-103 dihydropyrimidine dehydrogenase Homo sapiens 238-241 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 dihydropyrimidine dehydrogenase Homo sapiens 147-178 30944635-3 2019 Tegafur-uracil is an oral form of 5-fluorouracil whose efficacy is influenced by the activities of enzymes associated with its metabolism, such as dihydropyrimidine dehydrogenase (DPD), orotatephosphoribosyltransferase (OPRT) and thymidylate synthase (TS). Tegafur 0-14 dihydropyrimidine dehydrogenase Homo sapiens 180-183 28520376-7 2012 The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing recommendations for fluoropyrimidines (capecitabine, fluorouracil, and tegafur) based on DPYD genotype (3) (Table 1). Tegafur 155-162 dihydropyrimidine dehydrogenase Homo sapiens 173-177